Arcturus Therapeutics Holdings Inc. (ARCT)

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 3.

Arcturus Therapeutics (NASDAQ: ARCT) used a presentation at Guggenheim's 2026 Emerging Outlook Biotech Summit to highlight upcoming milestones for its messenger RNA (mRNA) rare disease pipeline, with CEO Joe Payne emphasizing progress in inhaled mRNA for cystic fibrosis (CF) and an intravenously dosed liver-targeted program for ornithine transcarbamylase (OTC) deficiency. Positioning as an mRNA medicines company

Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary cash support. ARCT is priced as a busted biotech with optionality; cash runway extends to 2028, but clinical and regulatory risks remain significant. ARCT-032's 12-week trial and ARCT-810's FDA alignment are key re-rating catalysts; both programs face pivotal data and regulatory endpoints.

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time. About Arcturus Found.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $14.17 and traded as low as $6.07. Arcturus Therapeutics shares last traded at $6.25, with a volume of 749,736 shares traded. Analysts Set New Price Targets A

Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference (Fireside Chat) Tuesday, December 2, 2025 (12:30 p.m. ET) About Arcturus Founded in 2013 and based i.

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have issued a buy

Arcturus Therapeutics Holdings Inc. ( ARCT ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Neda Safarzadeh - Vice President and Head of IR/PR & Marketing Joseph Payne - Founder, President, CEO & Director Andrew Sassine - CFO & Director Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Jake Batchelder - William Blair & Company L.L.C., Research Division Boran Wang - Guggenheim Securities, LLC, Research Division Angela Qian - Canaccord Genuity Corp., Research Division Kuan-Hung Lin - Wells Fargo Securities, LLC, Research Division Joohwan Kim Thomas Shrader - BTIG, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to a loss of $0.26 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the third quarter ended September 30, 2025, and provided corporate updates. “We were pleased to share the initial findings of ARCT-032 clinical activity with the CF community last month at the N.

NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Arcturus Therapeutics Holdings Inc. ("Arcturus") (NASDAQ: ARCT), resulting from allegations of providing potentially misleading business information to the investing public.

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter ended September 30, 2025 after the market close on Monday, November 10 and will also host a conference call and webcast at 4:30 pm Eastern Time on November 10, 2.

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Arcturus Therapeutics Holdings Inc.  ("Arcturus" or the "Company") (NASDAQ: ARCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.